Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling ...

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

The following is a summary of “Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage ...

It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in HR+ HER2-ve Breast ...

Thousands of women could benefit after tests showed the method was more effective than the current NHS offering.

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.